Skip to content
✕
Internet Explorer is no longer supported by this website.
For optimal browsing we recommend using
Chrome
,
Firefox
or
Safari
.
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Home Link (JNJ Logo)
Menu
Search
Toggle Menu
Change Country
Our Stories
Latest News
Innovation
Caring & Giving
Personal Stories
Health & Wellness
Our Heritage
Our Company
Our COVID-19 Efforts
The Road to a Vaccine
About J&J
Our Credo
Our Leadership Team
Living Our Values
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
J&J Health and Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Products
Consumer Health
MedTech
Pharmaceutical Products
Suppliers
Responsible Supply Base
Supplier-Enabled Innovation
Supplier Resources
Careers
What We Do
How We Hire
Job Spotlight
Employee Benefits
Students
Innovation
Career Stories
Media Center
Investors
2022 Annual Meeting of Shareholders
Corporate Governance
Quarterly Results
SEC Filings
News Releases
Pharmaceutical Pipeline
2021 Janssen Transparency Report
2021 Health for Humanity Report
ESG Investor Update
ESG Resources
Stock Information
Webcasts & Presentations
Investor Fact Sheet
Our Societal Impact
Global Community Impact
Global Public Health
Global Environmental Sustainability
Close Countries Menu
Explore more Johnson & Johnson sites:
Australia
alt
Argentina
alt
Brazil
alt
Canada
alt
Consumer Health
Janssen
MedTech
Chile
alt
China
alt
Colombia
alt
Costa Rica
alt
Czech Republic
Ecuador
alt
France
Germany
alt
India
alt
Japan
alt
Mexico
alt
New Zealand / Pacific
alt
Paraguay
alt
Peru
alt
Philippines
alt
Russia
alt
Switzerland
alt
German
English
French
United Kingdom
alt
United States
alt
Uruguay
alt
Venezuela
alt
Close Search Menu
Search input
Share
More HIV News
Innovation
March 29, 2022
U.S. FDA Approves CABENUVA (cabotegravir and rilpivirine) for Adolescents, Expanding the Indication of the First and Only Complete Long-Acting Injectable HIV Regimen
Innovation
March 24, 2022
U.S. FDA Approves Streamlined Process for Initiating HIV Therapy with CABENUVA (cabotegravir and rilpivirine), the First and Only Complete Long-Acting Injectable HIV Treatment
Innovation
February 01, 2022
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
Innovation
December 01, 2021
This Ring May Just Help Protect Women Against HIV
Our Company
December 01, 2021
World AIDS Day 2021: How Far We’ve Come, and Yet to Go
Innovation
November 30, 2021
How MenStar's MINA Campaign is Meeting the Needs of Men in the HIV Epidemic
Our Company
August 31, 2021
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
Innovation
July 26, 2021
The Sky’s the Limit: Drones Delivering HIV Supplies in Remote Uganda
Innovation
July 22, 2021
How Drones Are Being Used to Deliver Lifesaving HIV Drugs to Remote Areas of the World
Personal Stories
July 19, 2021
"1.5 Million Children Are Living With HIV in Sub-Saharan Africa. I'm One of the Doctors Treating These Young Patients Every Day"
Our Company
July 15, 2021
How the New Horizons Collaborative is Transforming Pediatric HIV in Uganda
Innovation
June 01, 2021
How Johnson & Johnson Has Pioneered in the Battle Against HIV/AIDS
Our Company
March 06, 2021
Janssen Announces 96-week Results of Phase 3b Study Demonstrating the Continued Safety and Efficacy of Long-acting HIV Treatment of Rilpivirine and Cabotegravir
Innovation
January 21, 2021
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
Innovation
December 21, 2020
Janssen Announces European Commission Authorisation of the First Complete Long-Acting Injectable HIV Treatment in Europe
Innovation
October 16, 2020
Janssen Receives Positive CHMP Opinion for Long-Acting Regimen for the Treatment of HIV
Innovation
March 20, 2020
Janssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIV
Innovation
March 11, 2020
Janssen Announces 48-week Results of Phase 3b Study Demonstrating the Safety and Efficacy of Long-Acting Injectable HIV Treatment of Rilpivirine and Cabotegravir Administered Every Two Months
Our Company
October 04, 2019
Johnson & Johnson Commits $500 Million Investment Over Four Years to Help End the Epidemics of HIV and Tuberculosis
Innovation
September 04, 2019
Johnson & Johnson Expands First-of-its-Kind Pediatric HIV Program to Zimbabwe
Innovation
July 23, 2019
Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen
We’re Committed to Helping Lead the Fight Against HIV/AIDS
Read about the many ways Johnson & Johnson is working to #makeHIVhistory.
Learn more
This site uses cookies as described in our
Cookie Policy
. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Reject
Accept
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue